ꯑꯦꯁ. ꯏ. ꯕꯤ. ꯑꯥꯏ. ꯅ ꯑꯦꯜꯒꯤ ꯔꯕꯔ ꯁꯦꯌꯔ ꯇ ꯭ ꯔꯥꯟꯁꯐꯔꯒꯤꯗꯃꯛ ꯂꯧꯊꯣꯛꯄꯒꯤ ꯀꯥꯡꯂꯣꯟꯁꯤꯡꯗꯒꯤ ꯏꯃꯨꯡ ꯃꯅꯨꯡꯒꯤ ꯇ ꯭ ꯔꯁ ꯭ ꯠ ꯑꯗꯨ ꯂꯧꯊꯣꯛꯈꯤ
ꯑꯣꯔꯗꯔ ꯑꯁꯤꯅ ꯕꯔꯅꯝ ꯁꯦꯀ ꯭ ꯌꯨꯔꯤꯇꯤꯖ ꯇ ꯭ ꯔꯁ ꯭ ꯇꯇ ꯑꯦꯜꯒꯤ ꯔꯕꯔ ꯀꯝꯄꯅꯤ ꯂꯤꯃꯤꯇꯦꯠꯇ ꯁꯦꯌꯔꯁꯤꯡ ꯂꯧꯊꯣꯛꯄꯒꯤ ꯋꯥꯐꯝ ꯊꯝꯅꯕ ꯁꯦꯕꯤꯅ ꯂꯧꯊꯣꯛꯄꯒꯤ ꯆꯠꯅ ꯀꯥꯡꯂꯣꯟꯁꯤꯡꯗꯒꯤ ꯑꯌꯥꯕ ꯄꯤ ꯫ ꯂꯧꯊꯣꯛꯄ ꯑꯁꯤ ꯄ ꯭ ꯔꯣꯃꯣꯇꯔ ꯁꯨꯗꯔꯁꯟ ꯕꯔꯥꯗꯔꯖꯗꯒꯤ ꯏꯃꯨꯡꯒꯤ ꯇ ꯭ ꯔꯁ ꯭ ꯠ ꯑꯃꯗ ꯃꯊꯪ ꯃꯊꯪ ꯂꯥꯛꯅꯕ ꯊꯧꯔꯥꯡ ꯇꯧꯅꯕꯒꯤꯗꯃꯛ ꯁꯦꯌꯔꯁꯤꯡ ꯂꯂꯣꯟ-ꯏꯇꯤꯛ ꯅꯠꯇꯕ ꯑꯣꯏꯅ ꯊꯥꯗꯣꯛꯄ ꯑꯃꯅꯤ ꯫
ꯑꯦꯜꯒꯤ ꯔꯕꯔ ꯀꯝꯄꯅꯤ ꯂꯤꯃꯤꯇꯦꯗ (ꯇ ꯭ ꯔꯒꯦꯠ ꯀꯝꯄꯅꯤ), ꯕꯔꯅꯝ ꯁꯦꯀ ꯭ ꯌꯨꯔꯤꯇꯤꯖ ꯇ ꯭ ꯔꯁ ꯭ ꯠ (ꯑꯦꯀ ꯭ ꯋꯤꯌꯔꯔ ꯇ ꯭ ꯔꯁ ꯭ ꯠ), ꯁꯨꯗꯔꯁꯟ ꯕꯔꯥꯗꯔꯖ (ꯄ ꯭ ꯔꯣꯃꯣꯇꯔ/ꯇ ꯭ ꯔꯁ ꯭ ꯇꯤ), ꯑꯦꯜ. ꯑꯥꯔ. ꯖꯤ. ꯇꯦꯛꯅꯣꯂꯣꯖꯤꯁ ꯂꯤꯃꯤꯇꯦꯗ (ꯏꯟꯇꯔꯃꯤꯗꯤꯌꯦꯔꯤ ꯑꯦꯟꯇꯤꯇꯤ), ꯍꯔꯁꯥ ꯕꯔꯥꯗꯔꯖ, ꯕꯔꯁꯤꯅꯤ ꯕꯔꯥꯗꯔꯖ, ꯖꯌꯔꯝ ꯕꯔꯥꯗꯔꯖ, ꯁꯨꯃꯟꯊ ꯔꯥꯃꯃꯨꯔꯊꯤ, ꯑꯟꯚꯔ ꯖꯌ ꯕꯔꯥꯗꯔꯖ, ꯃꯥꯌꯥ ꯖꯌ ꯕꯔꯥꯗꯔꯖ, ꯕꯔꯨꯟ ꯖꯌ ꯕꯔꯥꯗꯔꯖ, ꯑꯦꯜꯒꯤ ꯏꯀ ꯭ ꯋꯤꯞꯃꯦꯟ ꯭ ꯇꯁ ꯂꯤꯃꯤꯇꯦꯗ, ꯀ ꯭ ꯔꯣꯁ ꯭ ꯇꯦꯐ ꯖꯦꯝꯁ ꯏꯗꯟ, ꯁ ꯭ ꯔꯤꯅꯤꯙꯤ ꯒꯨꯔꯨꯁ ꯭ ꯋꯥꯃꯤ, ꯚꯥꯔꯇꯤ ꯕꯔꯥꯗꯔꯖ, ꯑꯦꯁ. ꯑꯥꯔ. ꯚꯦꯡꯀꯇꯆꯂꯝ, ꯑꯦꯝ. ꯗꯤ. ꯁꯦꯜꯚꯔꯖ ꯫
- ꯁꯦꯕꯤꯅ ꯁꯦꯕꯤ (ꯁꯕꯁ ꯭ ꯇꯦꯟꯇ ꯭ ꯌꯦꯜ ꯑꯦꯀ ꯭ ꯋꯤꯖꯤꯁꯟ ꯑꯣꯐ ꯁꯦꯌꯔꯁ ꯑꯦꯟ ꯇꯦꯛꯑꯣꯚꯔꯁ) ꯔꯦꯒꯨꯂꯦꯁꯟ, 2011ꯒꯤ ꯔꯦꯒꯨꯂꯦꯁꯟ 3 (1), 4, ꯑꯃꯁꯨꯡ 5ꯗꯒꯤ ꯑꯌꯥꯕ ꯄꯤꯈꯤ ꯫
- تجویز ꯇꯧꯔꯕ ꯇ ꯭ ꯔꯥꯟꯖꯦꯛꯁꯟ ꯑꯁꯤꯗ <ꯑꯥꯏ. ꯗꯤ. 3>, ꯁꯦꯌꯔ 350 (<ꯑꯥꯏ. ꯗꯤ. 1>%) ꯒꯤ ꯍꯛꯊꯦꯡꯅꯅ ꯊꯥꯗꯣꯛꯄ ꯑꯃꯁꯨꯡ ꯕꯔꯅꯝ ꯁꯦꯀ ꯭ ꯌꯨꯔꯤꯇꯤꯖ ꯇ ꯭ ꯔꯁ ꯭ ꯠꯅ ꯑꯦꯜ. ꯑꯥꯔ. ꯖꯤ. ꯇꯦꯛꯅꯣꯂꯣꯖꯤ (<ꯑꯥꯏ. ꯗꯤ. 2>) ꯒꯤ ꯈꯨꯠꯊꯥꯡꯗ ꯍꯛꯊꯦꯡꯅꯅ ꯂꯧꯊꯣꯛꯄ ꯌꯥꯎꯔꯤ ꯫
- ꯂꯧꯁꯤꯟꯕꯒꯤ ꯃꯑꯣꯡ ꯑꯁꯤ ꯈꯟꯅꯗꯅ ꯈꯨꯗꯣꯜ ꯑꯃ ꯑꯣꯏꯅ ꯁꯦꯝꯈꯤꯕꯅꯤ ꯫
- ꯇ ꯭ ꯔꯁ ꯭ ꯠ ꯑꯁꯤ ꯀꯥꯟꯅꯔꯕ ꯃꯄꯨ ꯑꯣꯏꯕ ꯅꯠꯇ ꯭ ꯔꯒ ꯂꯥꯛꯁꯤꯟꯕꯗ ꯍꯣꯡꯗꯣꯛꯇ ꯭ ꯔꯕ ꯄ ꯭ ꯔꯣꯃꯣꯇꯔꯁꯤꯡꯒꯤ ꯍꯣꯜꯗꯤꯡꯁꯤꯡꯒꯤ'ꯃꯤꯔꯔꯒꯤ ꯃꯃꯤ "ꯑꯃꯅꯤ ꯍꯥꯏꯅ ꯁꯦꯕꯤꯅ ꯄꯟꯈꯤ ꯫
- ꯑꯣꯔꯗꯔ ꯑꯁꯤꯅ ꯄꯕ ꯭ ꯂꯤꯛ ꯁꯦꯌꯔꯍꯣꯜꯗꯤꯡ ꯑꯁꯤ 34.97% ꯗ ꯍꯣꯡꯗꯅ ꯂꯩꯔꯤ ꯍꯥꯏꯕꯁꯤ ꯁꯣꯏꯗꯅ ꯈꯪꯍꯜꯂꯤ ꯫
- ꯑꯦꯄ ꯭ ꯂꯤꯀꯦꯁꯟ ꯑꯗꯨ 2026ꯀꯤ ꯃꯦ 19ꯗ ꯐꯥꯏꯜ ꯇꯧꯈꯤ ꯫
ꯑꯦ. ꯑꯥꯏ. ꯅ ꯗꯣꯀꯨꯃꯦꯟ ꯭ ꯇ ꯑꯗꯨꯗꯒꯤ ꯏꯈꯤ, ꯑꯃꯁꯨꯡ ꯃꯗꯨꯒꯤ ꯃꯥꯌꯣꯛꯇ ꯌꯦꯡꯁꯤꯟꯈꯤ ꯫ ꯃꯈꯥꯗ ꯄꯤꯔꯤꯕ ꯑꯁꯦꯡꯕ ꯑꯁꯤ ꯍꯛꯆꯤꯟꯕꯅꯤ ꯫
ꯑꯁꯦꯡꯕ ꯆꯦ ꯑꯗꯨ
ꯆꯦꯒꯤ ꯑꯀꯨꯞꯄ ꯃꯔꯣꯜꯁꯤꯡ
| ꯑꯣꯐꯤꯁ ꯭ ꯌꯦꯜ ꯇꯥꯏꯇꯦꯜ | ꯑꯦꯜꯒꯤ ꯔꯕꯔ ꯀꯝꯄꯅꯤ ꯂꯤꯃꯤꯇꯦꯗꯀꯤ ꯃꯇꯥꯡꯗ ꯑꯦꯛꯁꯞꯃꯦꯟꯁ ꯑꯣꯔꯗꯔ |
| ꯁꯣꯔꯁ ꯕꯣꯗꯤ | ꯁꯦꯀ ꯭ ꯌꯨꯔꯤꯇꯤꯁ ꯑꯦꯟꯗ ꯑꯦꯛꯆꯦꯟꯖ ꯕꯣꯔ ꯭ ꯗ ꯑꯣꯐ ꯏꯟꯗꯤꯌꯥ (ꯁꯦꯕꯤ)-ꯏꯟꯐꯣꯔꯁꯃꯦꯟ ꯭ ꯇ ꯑꯣꯔꯗꯔꯁꯤꯡ |
| ꯔꯤꯐꯔꯦꯟꯁ ꯅꯝꯕꯔ | WTM/KCV/CFD/07/2026-27 |
| ꯐꯤꯕꯝ | ꯑꯃꯠꯇ ꯂꯩꯇꯦ ꯫ (ꯑꯣꯔꯗꯔ) |
| ꯆꯍꯤ | 2026 |
| ꯂꯣꯏꯁꯤꯟꯕꯒꯤ ꯇꯥꯡ | — |
| ꯆꯦ-ꯆꯥꯡꯁꯤꯡ | 1 |